ADPT Adaptive Biotechnologies Corporation

$2.11 (5.65%)

ADPT Stock Analysis Overview

What this means: InvestorsObserver gives Adaptive Biotechnologies Corporation (ADPT) an overall rank of 45, which is below average. Adaptive Biotechnologies Corporation is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 45 means that 55% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Adaptive Biotechnologies Corporation (ADPT) Analyst Forecast

Next 12 months ➝Current Price$39.4352-week High$55.1252-week Low$15.19MEAN$49.67+25.96%HIGH$54.00+36.95%LOW$45.00+14.13%
  • Last Price$39.43
  • Previous Close$37.32
  • Change $2.11
  • Open$37.37
  • Volume903,065
  • Avg. Volume (100-day)1,138,284
  • Market Capitalization$5B
  • Days Range $37.33 - $39.94
  • 52-week Range $15.19 - $55.12
  • Dividend Yield
  • Ex. Dividend Date
  • P-E
  • EPS-1.63
  • Earnings Date08/10/2020
  • SectorHealthcare
  • IndustryBiotechnology
  • Avg. Analyst Rec.
  • Beta1.202
  • PEG Ratio
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.